Introduction
============

Pancreatic ductal adenocarcinoma (PDAC) is the fifteenth most common malignancy and is the seventh most common cause of cancer-related deaths worldwide [@B1]. Radical resection is the only curative option, but patients with resectable PDAC have a high risk of postsurgical recurrence and a poor overall prognosis [@B2].

In the 7^th^ edition of the American Joint Committee on Cancer (AJCC) staging scheme [@B3], extrapancreatic extension is considered a more important prognostic factor than tumor size because resectable PDAC with extrapancreatic extension is categorized as T3 regardless of tumor size. Additionally, patients with nodal metastasis are assigned to a single prognostic group---the N1 classification---regardless of the positive lymph node count [@B3].

Several studies have questioned the clinical relevance and reproducibility of the 7^th^ AJCC staging for patients with PDAC, especially the 7^th^ T3 classification which requires the identification of extrapancreatic extension [@B4]. In the recently proposed 8^th^ AJCC staging scheme [@B5], the definitions of T classifications for resectable PDAC were solely based on tumor size (T1, T2, and T3: ≤2 cm, \>2 cm and ≤4 cm, and \>4 cm, respectively), while the 7^th^ AJCC N1 classification was further stratified according to the positive lymph node count (N1: 1-3 positive nodes; N2: ≥4 positive nodes). However, in a recent US multi-institutional study, even though the reproducibility of the 8^th^ AJCC T classification system was found to be superior to that of the 7^th^ AJCC T classification system, the discriminatory power of the 7^th^ and 8^th^ AJCC schemes were still comparable[@B5].

In the present study, we first assessed the prognostic performance of the 7^th^ and 8^th^ AJCC classifications using a large population-based cohort of patients with resectable PDAC. Thereafter, we developed a refined staging scheme through objective regrouping of the 7^th^ and 8^th^ T classifications and the 8^th^ N classifications by using recursive partitioning analysis (RPA).

Methods
=======

Study cohort
------------

Using the National Cancer Institute\'s Surveillance, Epidemiology, and End Results (SEER) database (18 registries), we included 17379 patients with PDAC (NAACCR Item \#400 \[primary tumor site\], codes: C25.0-C25.4; NAACCR Item \#552 \[histologic type\], codes: 8140, 8150, 8210, 8211, 8251, 8260, 8261, 8263, 8480, 8481, 8490, 8500, and 8503) from January 2004 to December 2012. Exclusion criteria are as following: concurrent or with a history of prior malignancy, locally unresectable tumor (T4 classification), distant metastasis, tumor *in situ*, and missing information regarding tumor size, 6^th^ AJCC T and M classifications, and the number of positive nodes. The final study cohort comprised 8542 patients. PDAC in all cases was restaged on the basis of the 7^th^ and 8^th^ AJCC staging schemes.

Statistical analysis
--------------------

Overall survival (OS) was the primary outcome of interest. Stratified survival analyses with the Kaplan-Meier method and log-rank tests were used to evaluate the prognostic impact of the 7^th^ T classification within each of the 8^th^ T classifications and the prognostic impact of the 8^th^ T classification within each of the 7^th^ T classifications. Multivariate Cox regression was used to examine the association between the 7^th^ and 8^th^ T classifications and hazard ratios (HRs) for death after adjustment for the clinicopathologic factors. Additionally, the capacity of the 7^th^ and 8^th^ T classification systems to distinguish patients at low and high risk of death was quantified using the concordance index (C-index) [@B6]. The value of the C-index ranges from 0.5 to 1.0, with 0.5 indicating a random chance and 1.0 indicating a perfect ability to correctly determine the outcome. Thus, the higher the C-index, the greater is the discriminatory capacity of the scheme.

Two-thirds of the patients in the study cohort were randomly assigned to a training set (n = 5710) and the remaining one-third were assigned to a validation set (n = 2832) to develop and validate a refined staging system which combined the prognostic information of the 7^th^ and 8^th^ T classifications together with the 8^th^ N classifications using RPA. RPA can divide patients at each step into two groups based on the covariate that provided maximum separation with respect to prognosis and accounted for interactions between factors [@B7], [@B8].

In both the training and validation sets, the performance of the RPA staging scheme was compared with the 7^th^ and 8^th^ AJCC staging schemes in terms of prognostic stratification, discriminatory ability, and prognostic homogeneity. Prognostic stratification was assessed using stratified survival analyses, which evaluated the prognostic effect of a staging scheme within each substage of the other staging scheme. The discriminatory abilities of the three staging schemes were quantified using the C-index and Akaike\'s information criterion (AIC) [@B9]. The higher the C-index or the lower the AIC value, the greater was the discriminatory ability of the staging scheme. The likelihood ratio χ^2^ test was used to measure the prognostic homogeneity of the staging schemes [@B10]. The higher the likelihood ratio χ^2^ value, the greater was the prognostic homogeneity of the staging scheme.

Statistical significance was set at *P* \<0.05 in a two-tailed test. Statistical analyses were performed using SAS v. 9.3 (SAS Institute, Cary, NC, USA), IBM SPSS Statistics for Windows v. 19.0 (IBM Corp., Armonk, NY, USA), and R v. 3.3.1 (<http://www.r-project.org>). The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform ([www.researchdata.org.cn](http://www.researchdata.org.cn)), with the approval RDD number as RDDA2017000221.

Results
=======

**Table [1](#T1){ref-type="table"}**summarizes the characteristics of the study cohort (8542 cases). Most patients were diagnosed as having tumor extending beyond the pancreas (79.3%) and tumor with the greatest dimension \>2cm and ≤4cm (59.3%). Most patients had lymph node metastasis (64.3%), and the median positive and examined lymph node counts were 1 (interquartile range \[IQR\]: 0-3) and 13 (IQR: 7-19), respectively. The median survival period was 18 months.

Survival by T classification of the 7^th^ and 8^th^ AJCC schemes is presented in **Figure [1](#F1){ref-type="fig"}A and [1](#F1){ref-type="fig"}B**, respectively. In both systems, each T classification represented a distinct prognosis. After adjustment for race, year of diagnosis, age, sex, marital status, SEER region tumor site, tumor grade, and examined node count, higher 7^th^ and 8^th^ T classifications were associated with an increased risk of death (7^th^ edition: T2 vs. T1: HR, 1.49; *P* \<0.001; T3 vs. T1: HR, 1.79; *P* \<0.001; 8^th^ edition: T2 vs. T1: HR, 1.37; *P* \<0.001; T3 vs. T1: HR, 1.61; *P* \<0.001). Significant heterogeneity in median survival was identified in patients within the 7^th^ T3 classification when stratified by the 8^th^ T classification, and among patients within each of the 8^th^ T classifications when stratified by the 7^th^ T classification (**Table [2](#T2){ref-type="table"}**). For patients with 7^th^ T3N0 disease, the OS differed significantly between the 8^th^ T1, T2, and T3 classifications (median survival: 26, 20, and 16 months, respectively; *P*\<0.001); within each 8^th^ T classification, the OS was significantly different between patients with and without tumor extending beyond the pancreas (*P* \<0.01, *P* \<0.001, and *P* \<0.01 in the 8^th^ T1, T2, and T3 classifications, respectively). Of note, within the 8^th^ T1N0 classification, a 21-month difference in median survival was found between patients with 7^th^ T1 and T3 disease (**Table [2](#T2){ref-type="table"}**). Moreover, the 7^th^ and 8^th^ T classification systems exhibited similar discriminatory capacity among patients with node-negative disease (C-indices: 0.558 vs. 0.556, *P* =0.42).

We further assessed the consistency of predicted OS among patients with node-negative tumor extending beyond the pancreas across different SEER regions. We found that survival was homogeneous when stratified by SEER region in these patients (*P* =0.14; **Figure [1](#F1){ref-type="fig"}C**).

Patient and tumor characteristics were comparable among the training set and the validation set (**Table [3](#T3){ref-type="table"}**). The RPA algorithm classified the patients in the training set into the following five groups (**Figure [2](#F2){ref-type="fig"}**): RPA-IA (8^th^ T1N0 limited to the pancreas), RPA-IB (8^th^ T1N0 extending beyond the pancreas or 8^th^ T2-T3N0 limited to the pancreas), RPA-IIA (8^th^ T2N0 extending beyond the pancreas or 8^th^ T1N1-N2), RPA-IIB (8^th^ T3N0 extending beyond the pancreas or 8^th^ T2-T3N1), and RPA-III (8^th^ T2-T3N2). The RPA-IA, RPA-IB, RPA-IIA, RPA-IIB, and RPA-III stage groups included 226 (4.0%), 646 (11.3%), 1310 (22.9%), 2412 (42.2%), and 1116 (19.5%) of the patients in the training set, respectively. The corresponding median survival was 47, 28, 20, 16, and 14 months, respectively (*P* \<0.001;**Figure [3](#F3){ref-type="fig"}A**). A higher RPA stage was associated with an increased risk of death after adjusted for clinicopathologic factors (RPA-IB vs. RPA-IA: HR, 1.40; *P* \<0.01; RPA-IIA vs. RPA-IA: HR, 2.04; *P* \<0.001; RPA-IIB vs. RPA-IA: HR, 2.73; *P* \<0.001; RPA-III vs. RPA-IA: HR, 3.30; *P* \<0.001).

As shown in **Figure [3](#F3){ref-type="fig"}B and [3](#F3){ref-type="fig"}C**, each 7^th^ AJCC and 8^th^ AJCC stage represented a distinct prognosis in the training set. Using RPA staging, patients with each 8^th^ AJCC stage of disease and 7^th^ stage IIA and IIB disease could be further stratified into subgroups with remarkably different OS rates; in contrast, OS was homogeneous when the patients with each RPA stage of disease were re-stratified by the 7^th^ or 8^th^ AJCC systems (**Table [4](#T4){ref-type="table"}**). Of note, patients with 8^th^ stage IA disease (median survival: 36 months) could be further stratified into RPA-IIA and RPA-IA subgroups depending on the presence or absence of extrapancreatic extension, and a 21-month difference in median survival was found between patients classified as having RPA-IA and those classified as having RPA-IIA disease (47 vs. 26 months, *P* \<0.01). Additionally, patients with 8^th^ T3N0 tumors extending beyond the pancreas and 8^th^ T2-T3N1 tumors, who were classified into 8^th^ stage IIA and IIB groups, respectively, actually had similar survival (median survival: 16 months for both; *P* =0.43) and were both re-classified into RPA-IIB according to the RPA staging system. The findings in stratified analyses were consistent when applied to the validation set (**Table [5](#T5){ref-type="table"}**).

**Table [6](#T6){ref-type="table"}** lists the parameters used to measure the discriminatory ability and prognostic homogeneity of the RPA staging and the 7^th^ and 8^th^ AJCC staging schemes. For both the training and validation sets, the RPA staging system showed significantly greater discriminatory power than the 7^th^ and 8^th^ AJCC staging systems (training set: C-indices, 0.574 vs. 0.559; *P* \<0.001; validation set: C-indices, 0.575 vs. 0.558; *P* \<0.01) and the 8^th^ AJCC staging system (training set: C-indices, 0.574 vs. 0.564; *P* =0.03; validation set: C-indices, 0.575 vs. 0.562; *P* =0.04). The RPA staging scheme also outperformed the 7^th^ and 8^th^ AJCC staging schemes in terms of the AIC and the likelihood ratio χ^2^ value in both the training and validation sets.

Discussion
==========

The recently proposed 8^th^ AJCC staging scheme [@B5] has notable modifications in the T and N classifications compared to the 7^th^ staging scheme. Tumor size was the only factor considered to determine the 8^th^ T classification for resectable PDAC regardless of the involvement of peripancreatic soft tissue, whereas node-positive disease was further classified into N1 (1-3 positive nodes) and N2 classification (≥4 positive nodes) in the 8^th^ staging.

In the present study of patients with resectable PDAC from the SEER database, we first compared the performance of the 7^th^ and 8^th^ AJCC T classifications using stratified survival analyses. For patients with N0 disease, both the 7^th^ and 8^th^ AJCC T classification systems showed significant heterogeneity in survival when assessed against each other, suggesting that there is scope to improve both these schemes. Therefore, we performed RPA to develop a new staging scheme for resectable PDAC that incorporated the 7^th^ and 8^th^ T classifications along with the 8^th^ N classifications.

RPA is a kind of nonparametric multivariable analysis that can repeatedly dichotomize the study population into smaller and smaller subsets [@B7]. The process of binary stratification is repeated based on covariates that maximize the change in an index of diversity, which accounts for prior probabilities and penalties for misclassification [@B11], [@B12]. Additionally, RPA is able to identify synergistic interactions among covariates [@B11]. Moreover, Kattan *et al.* reported that the RPA-based model exhibited a superior predictive accuracy to the traditional Cox proportional hazards regression model [@B13].

RPA has been widely used in other malignancies [@B14]-[@B17]. One of the most common applications and advantages is that it is able to objectively and intuitively generate several risk-groups for a desired endpoint. For instance, Huang *et al.* performed RPA to regroup the current AJCC T and N classifications and proposed a RPA staging system for human papilloma virus (HPV)-related cancer [@B16]. Compared with the current AJCC staging for oropharyngeal cancer, the RPA staging significantly improved survival prediction for patients with HPV-related oropharyngeal cancer, without increasing complexity [@B16]. Another common application and advantage of RPA is that it is capable of identifying optimal cutoff values for continuous covariates of interests. For instance, by using RPA among patients with chronic lymphocytic leukemia, Cui *et al.* defined a threshold for ROR1 surface expression that could categorize the cohort into ROR1-High vs. ROR1-Low subgroups with significantly different survival outcomes [@B15].

For the training set, the RPA staging scheme outperformed the 7^th^ and 8^th^ AJCC staging schemes in terms of discriminatory power and in stratified survival analyses. Even though the RPA staging was only slightly better in terms of discrimination, it was considerably superior to the 7^th^ and 8^th^ AJCC schemes in stratified survival analyses. With the additional ability to distinguish survival between patients with PDAC of diameter ≤4 cm and those with PDAC of diameter \>4 cm, the RPA staging scheme was able to further stratify patients within the 7^th^ stage IIA and IIB group into different risk groups. Additionally, it is noteworthy that each 8^th^ AJCC stage group could be classified by the RPA system into subgroups with remarkably different OS rates. For example, the 8^th^ stage IA disease (8^th^ T1N0) was further stratified into RPA-IIA and RPA-IA disease depending on the presence or absence of extrapancreatic extension, and the difference in median survival between patients in these two groups exceeded 20 months. In contrast, OS was homogeneous within each RPA stage regardless of the 7^th^ and 8^th^ AJCC staging. For example, 8^th^ T3N0 tumors extending beyond the pancreas and 8^th^ T2-T3N1 tumors, which were classified into different prognostic subgroups on the basis of the 8^th^ AJCC staging (8^th^ stage IIA and IIB, respectively), actually had similar survival and were both classified into RPA-IIB. The results of the likelihood ratio χ^2^tests also support the findings from stratified survival analyses. Moreover, the predictive superiority of the RPA staging scheme was further verified using the validation set, which indicates minimal evidence of model overfit and the potential generalizability of the RPA staging scheme.

Currently, adjuvant chemotherapy followed by curative surgery is a standard treatment for PDAC [@B18], [@B19]. However, the OS benefits of adjuvant chemotherapy are modest (difference in median OS: \<5 months) in view of the results of the CONKO-001[@B20] and ESPAC-1 trials [@B21]. In this context, the RPA staging scheme will be clinically useful for treatment planning for the decision-making regarding adjuvant chemotherapy, which may help improve survival in selected patients and avoid overtreatment in others.

Prognostic nomograms that combine various prognostic factors, such as the one created by the Memorial Sloan-Kettering Cancer Center, have been proposed to refine survival prediction among patients with PDAC [@B22]. However, nomograms have not been widely used by patients and clinicians, probably due to their cumbersome nature and inherent complexities. In contrast, the proposed RPA staging scheme is based on the objective regrouping of the existing 7^th^ and 8^th^ AJCC stages, which are simple and widely accepted. Thus, it is important to note that the proposed RPA staging not only has a favorable prognostic performance but also is a convenient tool for treatment-related decision-making.

Previous studies investigating the prognostic impact of extrapancreatic extension have shown inconsistent findings [@B5], [@B22]-[@B28]. One possible explanation for this may be differences in the clinicopathologic characteristics of the included cases. Most studies that failed to detect a significant correlation between extrapancreatic extension and survival included patients with T4 disease [@B22], [@B23], [@B25], [@B28], which was regarded as unresectable, while all three studies that reported a negative correlation between extrapancreatic extension and survival excluded patients with T4 disease [@B5], [@B24], [@B27]. In the present study after excluding patients with T4 disease, we also identified prominent differences in survival between patients with and without tumor extending beyond the pancreas across all the 8^th^ T classifications.

The reproducibility of detecting extrapancreatic extension is a challenge for pathologists, because of the histologic complexity of the pancreas, including its lack of encapsulation and its complicated invaginations into peripancreatic soft tissue [@B4]. Allen *et al.* [@B5] reported that patients from different institutions classified as having 7^th^ T3N0 disease showed varying survival rates. However, in the present study of patients from the SEER database, survival rates were uniform among patients with 7^th^ T3N0 disease across different SEER regions. Although further studies to investigate the reproducibility of pathologic evaluation of extrapancreatic extension are necessary, our finding does support the stability of the 7^th^ AJCC T3 classification for prognosis in the general population.

The present study has some limitations. First, the measurement of tumor size was partially dependent on the percentage of tumor mesenchyme and the experience of the pathologist and may not always be accurate. Additionally, several important patient-level data were not available in the SEER data. For instance, because information regarding adjuvant chemotherapy was not reported, we could not evaluate how the proposed RPA staging may influence patient selection for adjuvant chemotherapy. Finally, this study was US-centric and patient cohorts from other countries are required to validate the RPA staging scheme.

In summary, we demonstrated that the prognostic accuracy of both the 7^th^ and 8^th^ AJCC T classification schemes needed improvement. Thus, we used population-based data and RPA to develop and validate a refined staging scheme for patients with resectable PDAC. The RPA staging system outperformed the 7^th^ and 8^th^ AJCC classification systems but was not substantially more complex. We expect that this newly proposed staging system will aid in decision-making regarding treatment and surveillance, as well as risk stratification in future prospective trials for patients with resectable PDAC.
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###### 

Clinicopathologic characteristics of the study cohort of patients with resectable PDAC (N =8542)

  Variable                                          Median (IQR)/N (%)
  ------------------------------------------------- --------------------
  Age, years                                        66 (58, 74)
  Race                                              
  White                                             7014 (82.1%)
  Black                                             896 (10.5%)
  Other/unknown                                     632 (7.4)
  Sex                                               
  Male                                              4332 (50.7%)
  Female                                            4210 (49.3%)
  Marital status                                    
  Married                                           5318 (62.3%)
  Unmarried                                         2992 (35.0%)
  Unknown                                           232 (2.7%)
  Year of diagnosis                                 
  2004-2006                                         2437 (28.5%)
  2007-2009                                         2966 (34.7%)
  2010-2012                                         3139 (36.7%)
  SEER region                                       
  Midwest                                           1352 (15.8%)
  Northeast                                         1611 (18.9%)
  South                                             1486 (17.4%)
  West                                              4093 (47.9%)
  Tumor site                                        
  Head                                              6641 (77.7%)
  Body                                              481 (5.6%)
  Tail                                              648 (7.6%)
  Overlapping/unknown                               772 (9.0%)
  Tumor grade                                       
  I/II                                              4863 (56.9)
  III/IV                                            2856 (33.5)
  Unknown                                           823 (9.6%)
  Tumor size                                        31 (25, 40)
  ≤2cm (8^th^ T1)                                   1466 (17.2%)
  \>2cm and ≤4cm (8^th^ T2)                         5063 (59.3%)
  \>4cm (8^th^ T3)                                  2013 (23.6%)
  7th AJCC T stage                                  
  T1 (≤2cm and limited to the pancreas)             550 (6.4%)
  T2 (\>2cm and ≤4cm and limited to the pancreas)   1216 (14.2%)
  T3 (extended beyond the pancreas)                 6776 (79.3%)
  Positive node count                               1 (0, 3)
  0 (8^th^ N0)                                      3049 (35.7%)
  1-3 (8^th^ N1)                                    2869 (33.6%)
  ≥4 (8^th^ N2)                                     2624 (30.7%)
  Examined node count                               13 (7, 19)

PDAC, pancreatic ductal adenocarcinoma; IQR, interquartile range; SEER, Surveillance, Epidemiology, and End Results; AJCC, American Joint Committee on Cancer.

###### 

Comparison of prognostic homogeneity between the 7^th^ and 8^th^ AJCC T classification schemes

  Staging scheme   7^th^ T1   7^th^ T2    7^th^ T3   *P* value^\*^                     
  ---------------- ---------- ----------- ---------- --------------- ----- ----------- ---------
  8^th^ T stage                                                                        
  8^th^T1          226        47 months   \-         \-              236   26 months   \<0.01
  8^th^ T2         \-         \-          298        32 months       821   20 months   \<0.001
  8^th^ T3         \-         \-          112        21 months       308   16 months   \<0.01
  *P* value^§^                \-                     0.08                  \<0.01      

AJCC, American Joint Committee on Cancer; RPA, recursive partition analysis

\*Comparison of OS within different 7^th^ T classifications. Bold*P*values indicate statistical significance (i.e., *P* \< 0.05).

§Comparison of OS within different 8th T classifications. Bold *P* values indicate statistical significance (i.e., P \< 0.05).

###### 

Characteristics of patients in the training and validation sets

  ---------------------------------------------------------------
  Variable                      Training set\   Validation set\
                                (N = 5710)\     (N = 2832)
  ----------------------------- --------------- -----------------
  Age, years                    66 (58-74)      66 (58-74)

  Race                                          

  White                         4688 (82.1)     2326 (82.1)

  Black                         602 (10.5)      294 (10.4)

  Other                         420 (7.3)       212 (7.5)

  Sex                                           

  Male                          2876 (50.4)     1456 (51.4)

  Female                        3227 (62.0)     1376 (48.6)

  Marital status                                

  Married                       3554 (62.2)     1764 (62.3)

  Unmarried                     2002 (35.1)     990 (35.0)

  Unknown                       154 (2.7)       78 (2.8)

  Year of diagnosis                             

  2004-2006                     1612 (28.2)     825 (29.1)

  2007-2009                     1989 (34.8)     977 (34.5)

  2010-2012                     2109 (36.9)     1030 (36.4)

  SEER region                                   

  Midwest                       901 (15.8)      451 (15.9)

  Northeast                     1110 (19.4)     501 (17.7)

  South                         1009 (17.7)     477 (16.8)

  West                          2690 (47.1)     1403 (49.5)

  Tumor site                                    

  Head                          4427 (77.5)     2214 (78.2)

  Body                          322 (5.6)       156 (5.6)

  Tail                          426 (7.5)       222 (7.8)

  Not specified                 535 (9.4)       237 (8.4)

  Tumor grade                                   

  I/II                          3277 (57.4)     1586 (56.0)

  III/IV                        1884 (33.0)     972 (34.4)

  Unknown                       549 (9.6)       274 (9.7)

  Tumor size                    31 (25-40)      31 (25-40)

  ≤2 cm (8^th^ T1)              951 (16.7)      515 (18.2)

  \>2 cm and ≤4 cm (8^th^ T2)   3366 (58.9)     1697 (59.9)

  \>4 cm (8^th^ T3)             1393 (24.4)     620 (21.9)

  7th AJCC T stage                              

  T1                            339 (5.9)       211 (7.5)

  T2                            833 (14.6)      383 (13.5)

  T3                            4538 (79.5)     2238 (79.0)

  Positive node count           1 (0-3)         1 (0-3)

  0 (8^th^ N0)                  2001 (35.0)     1048 (37.0)

  1-3 (8^th^ N1)                1967 (34.4)     902 (31.9)

  ≥4 (8^th^ N2)                 1742 (30.5)     882 (31.1)

  Examined node count           13 (7-19)       12 (7-19)
  ---------------------------------------------------------------

IQR, interquartile range; SEER, Surveillance, Epidemiology, and End Results; AJCC, American Joint Committee on Cancer.

###### 

Comparison of prognostic homogeneity between the 7^th^and 8^th^ AJCC schemes and the RPA staging scheme for the training set

  Staging scheme     RPA-IA   RPA-IB      RPA-IIA   RPA-IIB     RPA-III   *P* value^a^                                         
  ------------------ -------- ----------- --------- ----------- --------- -------------- ------ ----------- ------ ----------- ---------
  7^th^ AJCC stage                                                                                                             
  IA                 226      47 months   \-        \-          \-        \-             \-     \-          \-     \-          \-
  IB                 \-       \-          410       29 months   \-        \-             \-     \-          \-     \-          \-
  IIA                \-       \-          236       26 months   821       20 months      308    16 months   \-     \-          \<0.001
  IIB                \-       \-          \-        \-          489       20 months      2104   16 months   1116   14 months   \<0.001
  *P* value^b^       \-       \-                    0.37                  0.96                  0.47               \-          
  8^th^ AJCC stage                                                                                                             
  IA                 226      47 months   236       26 months   \-        \-             \-     \-          \-     \-          \<0.01
  IB                 \-       \-          298       32 months   821       20 months      \-     \-          \-     \-          \<0.001
  IIA                \-       \-          112       21 months   \-        \-             308    16 months   \-     \-          \<0.01
  IIB                \-       \-          \-        \-          367       22 months      2104   16 months   \-     \-          \<0.001
  III                \-       \-          \-        \-          122       18 months      \-     \-          1116   14 months   \<0.01
  *P* value^c^                \-                    0.15                  0.62                  0.43               \-          

AJCC, American Joint Committee on Cancer; RPA, recursive partition analysis

^a^Comparison of overall survival within different RPA stages. Bold *P* values indicate statistical significance (i.e., *P* \< 0.05).

^b^Comparison of overall survival within different 7^th^ AJCC stages. Bold *P* values indicate statistical significance (i.e., *P* \< 0.05).

^c^Comparison of overall survival within different 8^th^ AJCC stages. Bold *P* values indicate statistical significance (i.e., *P* \< 0.05).

###### 

Comparison of prognostic homogeneity between the 7^th^ and 8^th^ AJCC schemes and the RPA staging scheme for the validation set

  Staging scheme   RPA-IA   RPA-IB         RPA-IIA   RPA-IIB     RPA-III   P value^a^                                       
  ---------------- -------- -------------- --------- ----------- --------- ------------ ----- ----------- ----- ----------- ---------
  7th AJCC stage                                                                                                            
  IA               143      43 months^d^   \-        \-          \-        \-           \-    \-          \-    \-          \-
  IB               \-       \-             198       24 months   \-        \-           \-    \-          \-    \-          \-
  IIA              \-       \-             116       24 months   431       22 months    160   16 months   \-    \-          0.03
  IIB              \-       \-             \-        \-          256       21 months    977   16 months   551   15 months   \<0.001
  P value^b^       \-       \-                       0.72                  0.49               0.22              \-          
  8th AJCC stage                                                                                                            
  IA               143      43 months^d^   116       24 months   \-        \-           \-    \-          \-    \-          \<0.001
  IB               \-       \-             156       24 months   431       22 months    \-    \-          \-    \-          \<0.05
  IIA              \-       \-             42        19 months   \-        \-           160   16 months   \-    \-          0.11
  IIB              \-       \-             \-        \-          210       21 months    977   16 months   \-    \-          \<0.01
  III              \-       \-             \-        \-          46        21 months    \-    \-          551   15 months   0.01
  P value^c^                \-                       0.84                  0.77               0.22              \-          

AJCC, American Joint Committee on Cancer; RPA, recursive partition analysis

^a^Comparison of overall survival within different RPA stages. Bold *P* values indicate statistical significance (i.e., *P* \< 0.05).

^b^Comparison of overall survival within different 7^th^ AJCC stages. Bold *P* values indicate statistical significance (i.e., *P* \< 0.05).

^c^Comparison of overall survival within different 8^th^ AJCC stages. Bold *P* values indicate statistical significance (i.e., *P* \< 0.05).

^d^The median survival was not reached, and hence the mean survival time was provided instead.

###### 

Comparison of the performance of the RPA staging system with the 7^th^ and 8^th^ AJCC staging systems

  Model                    C-index   AIC        Likelihood ratio χ^2^
  ------------------------ --------- ---------- -----------------------
  For the training set                          
  RPA staging              0.574     59244.19   325.83
  7^th^ AJCC staging       0.559     59314.69   253.33
  8^th^ AJCC staging       0.558     59322.20   247.84
  For the validation set                        
  RPA staging              0.575     26755.91   174.34
  7^th^ AJCC staging       0.564     26780.06   148.18
  8^th^ AJCC staging       0.562     26793.34   136.80

RPA, recursive partitioning analysis; AJCC, American Joint Committee on Cancer; C-index, concordance index; AIC, Akaike\'s Information Criterion.
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